Literature DB >> 35641803

Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson's disease mouse model.

Mahsa Mobahat1, Esmaeil Sadroddiny1, Vajihe Taghdiri Nooshabadi2, Somayeh Ebrahimi-Barough3, Arash Goodarzi4, Ziba Veisi Malekshahi1, Jafar Ai5.   

Abstract

Parkinson disease (PD) is considered as one of the most worldwide neurodegenerative disorders. The major reasons associated to neurodegeneration process of PD pathogenesis are oxidative stress. Many studies reported that natural antioxidant molecules, especially, curcumin can suppress inflammatory pathways and preserve dopaminergic neurons damage in PD. Further, the poor pharmacokinetics, instability of chemical structure because of fast hydrolytic degradation at physiologic condition and especially, the presence of the blood brain barrier (BBB) has regarded as a considerable restriction factor for transfer of neurotherapeutic molecules to the brain tissue. The present research aims to the fabrication of nanoformulated curcumin loaded human endometrial stem cells derived exosomes (hEnSCs EXOs-Cur) to study on enhancing curcumin penetration to the brain across BBB and to improve anti- Parkinsonism effects of curcumin against neural death and alpha-synuclein aggregation. hEnSCs EXOs-Cur characterization results demonstrated the accurate size and morphology of formulated curcumin loaded exosomes with a proper stability and sustained release profile. In vivo studies including behavioral, Immunohistochemical and molecular evaluations displayed that novel formulation of hEnSCs EXO-Cur is able to cross BBB, enhance motor uncoordinated movements, suppress the aggregation of αS protein and rescue neuronal cell death through elevation of BCL2 expression level as an anti-apoptotic protein and the expression level reduction of BAX and Caspase 3 as apoptotic markers.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Alpha-synuclein; Anti-apoptosis; Blood-brain barrier; Curcumin; Exosomes; Parkinson’s disease

Year:  2022        PMID: 35641803     DOI: 10.1007/s10561-022-10008-6

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  40 in total

Review 1.  Alpha-synuclein and neurodegenerative diseases.

Authors:  M Goedert
Journal:  Nat Rev Neurosci       Date:  2001-07       Impact factor: 34.870

Review 2.  Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis.

Authors:  Vittorio Calabrese; Aurelia Santoro; Daniela Monti; Rosalia Crupi; Rosanna Di Paola; Saverio Latteri; Salvatore Cuzzocrea; Mario Zappia; James Giordano; Edward J Calabrese; Claudio Franceschi
Journal:  Free Radic Biol Med       Date:  2017-11-25       Impact factor: 7.376

Review 3.  Intranasal delivery to the central nervous system: mechanisms and experimental considerations.

Authors:  Shyeilla V Dhuria; Leah R Hanson; William H Frey
Journal:  J Pharm Sci       Date:  2010-04       Impact factor: 3.534

Review 4.  The epidemiology of Parkinson's disease: risk factors and prevention.

Authors:  Alberto Ascherio; Michael A Schwarzschild
Journal:  Lancet Neurol       Date:  2016-10-11       Impact factor: 44.182

5.  Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson's Disease: Modulation of Mitochondrial Perturbations.

Authors:  Noha F Abdelkader; Marwa M Safar; Hesham A Salem
Journal:  Mol Neurobiol       Date:  2014-12-15       Impact factor: 5.590

Review 6.  New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy.

Authors:  Robert A Hauser
Journal:  Parkinsonism Relat Disord       Date:  2009-12       Impact factor: 4.891

7.  Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.

Authors:  Anke A Dijkstra; Pieter Voorn; Henk W Berendse; Henk J Groenewegen; Annemieke J M Rozemuller; Wilma D J van de Berg
Journal:  Mov Disord       Date:  2014-07-03       Impact factor: 10.338

Review 8.  Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy.

Authors:  Brinda S Desai; Angela J Monahan; Paul M Carvey; Bill Hendey
Journal:  Cell Transplant       Date:  2007       Impact factor: 4.064

9.  Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.

Authors:  Daniel Alvarez-Fischer; Carmen Henze; Corinna Strenzke; Jan Westrich; Boris Ferger; Günter U Höglinger; Wolfgang H Oertel; Andreas Hartmann
Journal:  Exp Neurol       Date:  2007-11-01       Impact factor: 5.330

Review 10.  Expanding insights of mitochondrial dysfunction in Parkinson's disease.

Authors:  Patrick M Abou-Sleiman; Miratul M K Muqit; Nicholas W Wood
Journal:  Nat Rev Neurosci       Date:  2006-03       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.